Business Context and Reporting Period
This Form 8-K is a current report filed by Reneo Pharmaceuticals, Inc. (trading symbol: RPHM) on January 24, 2022, covering events occurring on January 18 and January 20, 2022. The registrant is a Delaware corporation headquartered in Irvine, California, and is classified as an emerging growth company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and director compensation arrangements rather than financial performance.
Material Changes
The filing discloses significant changes to the composition of the Board of Directors:
- Appointment: Paul Hoelscher was appointed as a Class I director, a member of the Audit Committee, and Chair of the Audit Committee (succeeding Eric Dube, Ph.D., who remains a member).
- Departure (Non-Re-election): Lon Cardon, Ph.D., will not stand for re-election as a Class I director upon the expiration of his term at the 2022 annual meeting due to his new role as President and CEO of The Jackson Laboratory.
- Resignation: Kenneth Harrison, Ph.D., resigned from the Board to focus on other endeavors.
- Reasoning: The filing explicitly states that neither Dr. Cardon's decision nor Dr. Harrison's resignation resulted from any dispute or disagreement with the Company regarding operations, policies, or practices.
Guidance, Outlook, and Compensation
The filing details the compensatory arrangements for the newly appointed director, Paul Hoelscher, pursuant to the Company's Non-Employee Director Compensation Policy:
- Cash Retainer: $40,000 annual cash retainer for Board service and an additional $15,000 annual cash retainer for serving as Chair of the Audit Committee.
- Equity Grant: An option to purchase 35,000 shares of common stock granted on the date of appointment, vesting in equal monthly installments over three years.
- Future Grants: Eligibility for automatic annual option grants on the date of each annual meeting of stockholders (pro-rated for the first year), vesting in full on the earlier of the one-year anniversary or the day prior to the next annual meeting.
- Change in Control: All option grants vest in full in the event of a change in control.
The filing contains no specific guidance, outlook, or discussion of risks and contingencies beyond the standard disclosure of director departures.
Investor Verification Checklist
- Verify the updated composition of the Board of Directors and Audit Committee on the Company's investor relations website.
- Review the Company's 2021 Equity Incentive Plan to understand the specific terms of the "change in control" provision mentioned in the director grants.
- Confirm the date of the 2022 annual meeting of stockholders to determine the exact expiration of Dr. Cardon's term.
- Check subsequent filings (e.g., 10-K or 10-Q) for financial metrics, as this 8-K does not contain financial data.